161 related articles for article (PubMed ID: 57505)
1. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
[TBL] [Abstract][Full Text] [Related]
2. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
[TBL] [Abstract][Full Text] [Related]
3. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
[TBL] [Abstract][Full Text] [Related]
5. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
[TBL] [Abstract][Full Text] [Related]
7. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
[TBL] [Abstract][Full Text] [Related]
8. Hemodialysis bone disease: correlation between clinical, histologic, and other findings.
Alvarez-Ude F; Feest TG; Ward MK; Pierides AM; Ellis HA; Peart M; Simpson W; Weightman D; Kerr DN
Kidney Int; 1978 Jul; 14(1):68-73. PubMed ID: 682426
[TBL] [Abstract][Full Text] [Related]
9. Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
Mora Palma FJ; Ellis HA; Cook DB; Dewar JH; Ward MK; Wilkinson R; Kerr DN
Q J Med; 1983; 52(207):332-48. PubMed ID: 6647748
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
[No Abstract] [Full Text] [Related]
11. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
[No Abstract] [Full Text] [Related]
12. Osteomalacic dialysis osteodystrophy: a trial of phosphate-enriched dialysis fluid.
Feest TG; Ward MK; Ellis HA; Aljama P; Kerr DN
Br Med J; 1978 Jan; 1(6104):18-20. PubMed ID: 620130
[TBL] [Abstract][Full Text] [Related]
13. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA
Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683
[TBL] [Abstract][Full Text] [Related]
15. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
Peacock M; Aaron JE; Walker GS; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
[No Abstract] [Full Text] [Related]
16. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
[TBL] [Abstract][Full Text] [Related]
17. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
Malluche HH; Goldstein DA; Massry SG
Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
[No Abstract] [Full Text] [Related]
18. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
von Herrath D; Kraft D; Schaefer K; Krempien B
MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
[No Abstract] [Full Text] [Related]
19. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients.
Heaf JG; Nielsen LP; Mogensen NB
Nephron; 1983; 35(2):103-7. PubMed ID: 6621754
[TBL] [Abstract][Full Text] [Related]
20. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
